NASDAQ:CLYM Climb Bio Q2 2026 Earnings Results & Report $11.00 +0.14 (+1.29%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$10.80 -0.20 (-1.85%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Climb Bio beat analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.18 versus the -$0.2093 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call7:00 AM ET Climb Bio EPS ResultsActual EPS-$0.18Consensus EPS -$0.2093Beat/MissBeat by +$0.0293One Year Ago EPSN/AEPS Beat Rate4 of last 7 quartersClimb Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsClimb Bio's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Climb Bio Q2 2026 Earnings FAQ Did Climb Bio beat earnings estimates for Q2 2026? Climb Bio (NASDAQ:CLYM) reported earnings of -$0.18 per share for Q2 2026, beating the consensus estimate of -$0.2093. The report was announced on Thursday, August 6, 2026. When is Climb Bio's next earnings date? Climb Bio's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Climb Bio on the company's earnings history page. Climb Bio Earnings HeadlinesClimb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing IntervalOctober 7 at 2:00 PM | seekingalpha.comBTIG Reaffirms Their Buy Rating on Climb Bio (CLYM)October 5, 2026 | theglobeandmail.comThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before they ever place a trade. This free guide from Base Camp Trading takes a different approach, starting with the basics and showing you exactly how options work, why traders use them, and how they fit into a simple trading plan.October 10 at 1:00 AM | Base Camp Trading (Ad)Climb Bio (NASDAQ:CLYM) Stock Dropped to Sell by Wall Street ZenOctober 3, 2026 | americanbankingnews.comClimb Bio to Present Preliminary Phase 2 Budoprutug Data in Primary Membranous Nephropathy at ASN Kidney Week 2026October 2, 2026 | quiverquant.comQClimb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and BudoprutugOctober 2, 2026 | globenewswire.comSee More Climb Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Climb Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Climb Bio and other key companies, straight to your email. Email Address About Climb BioClimb Bio (NASDAQ:CLYM) is a clinical-stage biotechnology company focused on developing novel therapies for patients with immune-mediated diseases, including autoimmune disorders. The company’s research is centered on addressing underlying drivers of abnormal immune activity and developing treatments intended to provide durable disease control. Climb Bio’s activities include the discovery, development and clinical evaluation of investigational biologic medicines. Its programs are designed to target pathways involved in B-cell function, autoantibody production and other mechanisms that contribute to autoimmune disease. The company’s pipeline remains in development, and its product candidates have not necessarily received regulatory approval. Climb Bio serves the global biopharmaceutical and healthcare markets through its research and clinical-development activities. Additional information about its commercial products, geographic operations and leadership is limited, as the company remains focused primarily on advancing its early-stage development programs.View Climb Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
